Clinical Trial Update: Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial of trebananib (AMG 386) in combination with docetaxel for advanced urothelial carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Trebananib (AMG 386) (trebananib)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Urothelial Carcinoma | Phase 2 | Status: WITHDRAWN